Inhaled nitric oxide developer Third Pole Therapeutics has announced the appointment of Bill Athenson as its new Chief Executive Officer, succeeding founding CEO David Zapol. Athenson most recently served as CEO of Three Lakes Partners; his previous experience includes 13 years as the VP, Global Sales, Marketing and Business Development at Nanosphere Inc. In … [Read more...] about Third Pole Therapeutics names Bill Athenson as CEO
News
Vectura names Will Downie as CEO and Executive Director
Inhaled drug developer Vectura has announced the appointment of former Catalent executive Will Downie as CEO and Executive Director. Downie was most recently Senior VP, Global Sales and Marketing at Catalent and previously served in various roles at GE Healthcare, Amersham Health, and Quintiles. In July 2019, Vectura announced that it would focus its R&D … [Read more...] about Vectura names Will Downie as CEO and Executive Director
Micro-Sphere to add spray drying capacity
CDMO Micro-Sphere has announced an investment of 3.5 million CHF (~$3.5 million) that will include the addition of a fifth spray drying line to its GMP facility in Switzerland. The new line should be in operation by the first quarter of 2021. According to the company, the expansion is needed due to increased demand for both spray drying and capsule filling for DPIs. … [Read more...] about Micro-Sphere to add spray drying capacity
Iconovo to develop generic Ellipta DPI platform
Dry powder inhaler developer Iconovo has announced that the company will invest approximately 20 million SEK over about 3 years to develop a new platform for development of generic versions of Ellipta DPI products. The platform will include a new device called ICOpre and custom dry powder formulations that will be pre-filled. The company said that the generic … [Read more...] about Iconovo to develop generic Ellipta DPI platform
Bryn Pharma raises $17.5 million to fund regulatory and commercial activities for its epinephrine nasal spray
Bryn Pharma, which recently announced that it would use Aptar's Bidose nasal device for delivery of its BRYN-NDS1C intranasal epinephrine, said that it has raised $17.5 million that it will use to prepare for US regulatory approval and commercialization of the nasal spray. BRYN-NDS1C has received Fast Track designation from the FDA, and the company plans to pursue … [Read more...] about Bryn Pharma raises $17.5 million to fund regulatory and commercial activities for its epinephrine nasal spray
TFF Pharmaceuticals announces IPO
TFF Pharmaceuticals, which is developing DPI formulations based on its thin film freezing (TFF) technology, has announced an initial public offering of 4,400,000 shares of common stock at $5.00 per share. Earlier this year TFF announced that it had raised $8.17 million through a Series A preferred stock offering. The company said that it expects to use the net … [Read more...] about TFF Pharmaceuticals announces IPO
Studies show Penthrox is superior to standard of care for acute trauma pain
Medical Developments International (MDI) has announced data from multiple European studies demonstrating the benefits of MDI's Penthrox methoxyflurane inhaler for the treatment of pain from acute trauma. Among the findings announced, Penthrox was shown to be superior to intravenous morphine, NSAIDS, paracetamol (acetaminophen), and ketoprofen in trauma settings; … [Read more...] about Studies show Penthrox is superior to standard of care for acute trauma pain
FDA clears BlueWillow IND for intranasal anthrax vaccine
The FDA has cleared BlueWillow Biologics' IND for its BW-1010 intranasal anthrax vaccine, and a Phase 1 trial of the vaccine is planned for later this year, the company said. Earlier this year, BlueWillow (formerly NanoBio) announced that it had received a patent for the anthrax vaccine, which is formulated with the company's NanoVax adjuvant. BW-1010 is in … [Read more...] about FDA clears BlueWillow IND for intranasal anthrax vaccine
Seelos Therapeutics says it has amended agreement for development of its intranasal ketamine
Seelos Therapeutics has announced an amendment of its agreement with Vyera Pharmaceuticals regarding development of SLS-002 intranasal ketamine. According to Seelos, the company will now not be required to conduct a Phase 3 trial and will make cash and stock payments to Vyera instead of a milestone that would be due on initiation of a Phase 3 trial. Seelos said … [Read more...] about Seelos Therapeutics says it has amended agreement for development of its intranasal ketamine
HCmed introduces Pulmogine nebulizer
HCmed Innovations has introduced its new Pulmogine mesh nebulizer, which is capable of delivering a variety of drugs for inhalation, including biologics and high viscosity solutions. The nebulizer is customizable for specific formulations, and the company says that it can effectively deliver drugs such as dornase alfa, colistin, and tobramycin for the treatment of … [Read more...] about HCmed introduces Pulmogine nebulizer